---
title: "CONTEC released its performance for the first three quarters, with a net profit attributable to the parent company of 9.3998 million yuan, a decrease of 5.08%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263273613.md"
description: "According to the Zhitong Finance APP, CONTEC released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 344 million yuan, a year-on-year increase of 3.03%. The net profit attributable to shareholders of the listed company was 9.3998 million yuan, a year-on-year decrease of 5.08%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 3.3972 million yuan. The basic earnings per share were 0.0234 yuan"
datetime: "2025-10-29T11:20:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263273613.md)
  - [en](https://longbridge.com/en/news/263273613.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263273613.md)
---

# CONTEC released its performance for the first three quarters, with a net profit attributable to the parent company of 9.3998 million yuan, a decrease of 5.08%

According to the Zhitong Finance APP, CONTEC (300869.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 344 million yuan, a year-on-year increase of 3.03%. The net profit attributable to shareholders of the listed company was 9.3998 million yuan, a year-on-year decrease of 5.08%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 3.3972 million yuan. The basic earnings per share were 0.0234 yuan

### Related Stocks

- [300869.CN](https://longbridge.com/en/quote/300869.CN.md)

## Related News & Research

- [Climate change threatens to reduce ‘le camping’ to ash](https://longbridge.com/en/news/294586739.md)
- [Elon Musk Sees Humans on Mars in 5–7 Years — And He Has $112 Billion Riding on It](https://longbridge.com/en/news/294402920.md)
- [Fresenius says FDA, EMA accept Vedolizumab biosimilar PB016 filings for review](https://longbridge.com/en/news/294463337.md)
- [05:30 ETBest Sharps Mail-Back Solutions for Small Medical Practices (2026): Sharps Assure Recognized by Expert Consumers](https://longbridge.com/en/news/294489182.md)
- [NichiiGakkan signs cooperation pact with Aomori’s Sannohe Town on remote medical administration](https://longbridge.com/en/news/294472915.md)